VBI Vaccines (VBIV) just unveiled an update.
VBI Vaccines Inc. is set to unveil promising early results from a Phase 2b study of its cancer vaccine candidate, VBI-1901, targeting recurrent glioblastoma at the upcoming World Vaccine Congress. This key presentation, detailing the vaccine’s tumor response data, will be part of the company’s ongoing dialogue with the investment community, shared at various industry events. The anticipation for this reveal is high, as it marks a significant milestone in the company’s efforts to advance cancer immunotherapy.
See more data about VBIV stock on TipRanks’ Stock Analysis page.
